1) Brusini P, Johnson CA. Staging functional damage in glaucoma: review of different classification methods. Surv Ophthalmol 2007;52:156-79.
2) Ederer F, Gaasterland DE, Sullivan EK; AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods and baseline characteristics of study patients. Control Clin Trials 1994;15:299-325.
3) Musch DC, Lichter PR, Guire KE, Standardi CL. The collaborative initial glaucoma treatment study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology 1999;106:653-62.
4) Leske MC, Heijl A, Hyman L, Bengtsson B. Early manifest glaucoma trial: design and baseline data. Ophthalmology 1999;106:2144-53.
5) Gordon MO, Kass MA. The ocular hypertension treatment study: design and baseline description of the participants. Arch Ophthalmol 1999;117:573-83.
7) Caprioli J. The importance of rates in glaucoma. Am J Ophthalmol 2008;145:191-2.
8) Bengtsson B, Patella VM, Heijl A. Prediction of glaucomatous visual field loss by extrapolation of linear trends. Arch Ophthalmol 2009;127:1610-5.
9) Bengtsson B, Heijl A. A visual field index for calculation of glaucoma rate of progression. Am J Ophthalmol 2008;145:343-53.
10) Park CS, Yoon HS, Rho SH. Characteristecs of visual field progression in normal tension glaucoma. J Korean Ophthalmol Soc 1998;39:1831-42.
12) Smith SD, Katz J, Quigley HA. Analysis of progressive change in automated visual fields in glaucoma. Invest Ophthalmol Vis Sci 1996;37:1419-28.
13) Caprioli J, Mock D, Bitrian E, et al. A method to measure and predict rates of regional visual field decay in glaucoma. Invest Ophthalmol Vis Sci 2011;52:4765-73.
14) Chen A, Nouri-Mahdavi K, Otarola FJ, et al. Models of glaucomatous visual field loss. Invest Ophthalmol Vis Sci 2014;55:7881-7.
15) Nouri-Mahdavi K, Hoffman D, Ralli M, Caprioli J. Comparison of methods to predict visual field progression in glaucoma. Arch Ophthalmol 2007;125:1176-81.
16) Azarbod P, Mock D, Bitrian E, et al. Validation of point-wise exponential regression to measure the decay rates of glaucomatous visual fields. Invest Ophthalmol Vis Sci 2012;53:5403-9.
18) Wong YL, Saw SM. Epidemiology of pathologic myopia in Asia and worldwide. Asia Pac J Ophthalmol (Phila) 2016;5:394-402.
20) Heijl A, Bengtsson B. The effect of perimetric experience in patients with glaucoma. Arch Ophthalmol 1996;114:19-22.
21) Chatfield C. Linear Systems. In: Chatfield C, ed. The Analysis of Time Series: Theory and Practice, 1st ed. Boston: Springer, 1975;277.
23) Bryan SR, Vermeer KA, Eilers PH, et al. Robust and censored modeling and prediction of progression in glaucomatous visual fields. Invest Ophthalmol Vis Sci 2013;54:6694-700.
24) Ahrlich KG, De Moraes CG, Teng CC, et al. Visual field progression differences between normal-tension and exfoliative hightension glaucoma. Invest Ophthalmol Vis Sci 2010;51:1458-63.
25) Park HY, Park SH, Park CK. Central visual field progression in normal-tension glaucoma patients with autonomic dysfunction. Invest Ophthalmol Vis Sci 2014;55:2557-63.
26) Chauhan BC, Drance SM, Douglas GR, Johnson CA. Visual field damage in normal-tension and high-tension glaucoma. Am J Ophthalmol 1989;108:636-42.
27) Tan NYQ, Sng CCA, Jonas JB, et al. Glaucoma in myopia: diagnostic dilemmas. Br J Ophthalmol 2019;103:1347-55.
29) Kimura Y, Hangai M, Morooka S, et al. Retinal nerve fiber layer defects in highly myopic eyes with early glaucoma. Invest Ophthalmol Vis Sci 2012;53:6472-8.
30) Sun Y, Lin C, Waisbourd M, et al. The impact of visual field clusters on performance-based measures and vision-related quality of life in patients with glaucoma. Am J Ophthalmol 2016;163:45-52.